Clinical Trial Update: A Phase II Study of CCX282-B in Patients With Celiac Disease [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase II study evaluating CCX282-B in patients with celiac disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Celiac Disease

Drugs mentioned

• CCX282-B (CCR9 antagonist)

Snippet

Sponsor: Amgen | Conditions: Celiac Disease | Phase 2 | Status: COMPLETED